A quiet outrage is building within the ranks of the U.S. military. Hundreds of millions of taxpayer dollars – nearly three-quarters of a billion – are being funneled not into bolstering combat readiness, but into weight loss medications like Ozempic. This startling revelation has sparked criticism from veterans and active-duty personnel alike, who question whether this is a genuine solution or a costly band-aid on a deeper problem.
The numbers are staggering. Since 2021, the Defense Logistics Agency has spent $726 million on GLP-1 medications, with $274.6 million allocated in a single fiscal year. Over 102,000 individual purchases paint a picture of widespread reliance on pharmaceutical intervention to address a growing obesity crisis within the armed forces. The scale of this expenditure has ignited a firestorm of frustration.
A 2025 report from the American Security Project revealed a troubling trend: a full 68 percent of the Reserve and National Guard forces are classified as overweight. Secretary of War Pete Hegseth publicly declared this “completely unacceptable,” vowing to reinstate “REAL fitness & weight standards.” But for many, the massive investment in drugs feels like a betrayal of those very standards.
Retired Navy Medical Service Corps officer Lt. Ted Macie is among the most vocal critics. He points to a dramatic surge in obesity rates within the military over the last decade – a 190 percent increase between 2016 and 2023. Macie argues that Ozempic and similar drugs are “yet another bandage on a broken leg,” a nearly billion-dollar fix for “avoidable poor choices.”
His concern extends beyond the financial burden. Macie warns of potentially serious side effects – bone and muscle loss, vision problems, kidney issues – consequences that could undermine the very readiness the military seeks to maintain. He believes the message being sent is deeply contradictory: promoting fitness while simultaneously accommodating and even enabling unhealthy lifestyles.
Sergeant First Class Josh Snodgrass, a 20-year veteran of the 82nd Airborne Division, echoes this sentiment. “Spending hundreds of millions on drugs like Ozempic raises a basic question: what are the long-term health effects, especially when used broadly across a force?” he asks, drawing a parallel to the rapid adoption of the COVID-19 vaccine before its full impact was understood.
Snodgrass’s frustration stems from a perceived erosion of standards during his final years of service. He observed weight control issues creeping into all branches, even elite units like Special Forces. The root of the problem, he believes, lies not at the unit level, but in basic training – the crucial foundation where discipline, accountability, and adherence to standards should be instilled.
The Army already possesses established programs to address weight issues, offering service members time and resources for correction. However, Snodgrass laments that these systems are rarely enforced effectively. “Leadership actually enforcing the standard” is the key, he insists, but that commitment appears to be lacking. He questions whether individuals requiring ongoing pharmaceutical support can truly be considered fit for service.
An active-duty Army Green Beret, speaking anonymously, expressed outright disbelief at the cost. “You’ve got to be freaking kidding me,” he stated, deeming the expenditure “outrageous” and “antithetical” to the military’s core values of fitness and uniformity. He fears the lack of clear criteria and vetting processes will inevitably lead to abuse of the system.
The core concern, shared by all three individuals, is a fundamental one: this massive investment represents a shortsighted “fix” that fails to address the underlying issues of discipline, accountability, and leadership within the armed forces. It’s a costly detour from the principles that have long defined military excellence, and a burden that taxpayers will ultimately bear.
